Details of the Drug Combination

General Information of Drug Combination (ID: DCE2X0G)

Drug Combination Name
Caspofungin Ibrexafungerp
Indication
Disease Entry Status REF
Candidiasis, Invasive Phase 3 [1]
Component Drugs Caspofungin   DMGQIPT Ibrexafungerp   DMK1IPV
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Caspofungin
Disease Entry ICD 11 Status REF
Candidiasis 1F23 Approved [2]
Fungal infection 1F29-1F2F Approved [3]
Mycoses 1F2Z Approved [2]
Mycosis fungoides 2B01 Approved [2]
Candidemia 1F23.3Y Investigative [2]
Esophageal candidiasis N.A. Investigative [2]
Caspofungin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fungal 1,3-beta-glucan synthase (Fung GSC2) TT0SFXH FKS2_YEAST Modulator [7]
------------------------------------------------------------------------------------
Caspofungin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Indication(s) of Ibrexafungerp
Disease Entry ICD 11 Status REF
Vulvovaginal Candidiasis 1F23.10 Approved [4]
Invasive candidiasis 1F23 Phase 3 [5]
Fungal infection 1F29-1F2F Phase 2 [6]
Ibrexafungerp Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fungal 1,3-beta-glucan synthase (Fung GSC2) TT0SFXH FKS2_YEAST Inhibitor [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05178862) A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
2 Caspofungin FDA Label
3 Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
4 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214900.
5 ClinicalTrials.gov (NCT03059992) Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI). U.S. National Institutes of Health.
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031918)
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
9 Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.